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ptimal Blood Pressure
evels in Patients With
oronary Artery Disease*
onathan Tobis, MD, FACC,
regg C. Fonarow, MD, FACC
os Angeles, California
ypertension is very prevalent and represents an important
odifiable risk factor for coronary artery disease. Current
uidelines recommend treatment of blood pressure (BP) to
evels of 140/90 mm Hg, irrespective of the presence or
bsence of coronary artery disease (in those without coex-
sting diabetes or chronic kidney disease) (1). However, few
linical trials have specifically evaluated the relationship of
reatment to different BP levels and cardiovascular events.
pidemiologic studies have suggested that BP 115/75 mg
g is associated with the lowest rates of cardiovascular
vents in the general population (2). However, concerns
ave been raised that lowering BP too far in patients with
oronary artery disease may compromise myocardial blood
ow. Indeed, a number of observational studies have sug-
ested that a J-curve exists with higher cardiovascular event
ates in patients with lower on-treatment BP, especially
iastolic BP 80 mm Hg. In the INVEST (International
erapamil-Trandolapril Study), a trial in 22,000 patients
ith hypertension and coronary artery disease, lower dia-
tolic BP was associated with a significant increased risk of
yocardial infarction (3). In the subgroup of patients with
oronary artery disease in the prospective randomized hy-
ertension optimal treatment, a J-curve relationship be-
ween treated diastolic BP (80 mm Hg) and myocardial
nfarction also was observed (4). As such, the optimal BP
evels in patients with coronary artery disease have been far
rom clear.
See page 833
The CAMELOT (Comparison of Amlodipine Versus
nalapril to Limit Occurrences of Thrombosis) trial as-
essed the effect of antihypertensive therapy in 1,991 pa-
ients with coronary artery disease present on angiography
nd BP in the “normal” range as defined by the investigators
s a diastolic BP 100 mm Hg (5). The therapeutic
ntervention groups were randomized to placebo, 10 mg
mlodipine, or 20 mg enalapril daily on a background of
tandard care therapies. The primary outcomes consisted of
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.t
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ular death, myocardial infarction, cardiac arrest, percuta-
eous coronary intervention or coronary artery bypass graft-
ng surgery, hospitalization with angina or congestive heart
ailure, stroke or transient ischemic attack, and new periph-
ral vascular disease. The study, published in 2004, reported
hat amlodipine, but not enalapril, decreased the composite
f cardiovascular events significantly compared with placebo
hazard ratio 0.69; p  0.003) (5). An intravascular ultra-
ound (IVUS) substudy was performed in 274 patients and
howed progression of coronary atherosclerosis in the
lacebo-treated patients (p  0.001). However, no progres-
ion of atherosclerosis was observed with either enalapril or
mlodipine. With both active treatment groups combined,
here appeared to be no significant progression of athero-
clerosis with reduction in systolic BP of approximately 10
m Hg and evidence of regression with reductions 10
m Hg. This decrease in cardiovascular events and regres-
ion of coronary atherosclerosis occurred in the presence of
trong adherence to the secondary prevention guidelines in
lace at the time the study was conducted. The mean
ow-density lipoprotein (LDL) in study subjects was 100
g/dl, and 95% of patients received aspirin, 83% were on a
tatin, and 76% were taking a beta-blocker (5). These
ndings suggest that achieving a systolic BP substantially
elow 140 mm Hg in patients with pre-existing coronary
rtery disease is associated with lower risk of clinical events,
ithout any evidence of a J-curve.
The paper by Sipahi et al. (6) in this issue of the Journal
urther extend the findings from the CAMELOT trial. For
his post hoc analysis, the 274 patients in the IVUS study
ere divided into 3 groups depending on their baseline BP:
ormal defined as 120/80 mm Hg, pre-hypertensive
efined as BP 120 to 139/80 mm Hg to 89 mm Hg, and
ypertensive defined as BP 140/90 mm Hg. There were
o significant baseline differences in these groups in the
mount of atheroma present on the IVUS studies as defined
s the percentage atheroma volume (%AV). The major
nding was that the hypertensive group showed significant
rogression of atherosclerotic vascular disease (mean in-
rease %AV of 12 mm3) compared with the normotensive
roup who had a reduction (regression) in %AV of 4.6 mm3.
he pre-hypertensive group had no significant change in
AV. The atheroma progression rate was also significantly
ower in the group that had transition from pre-hypertensive
o normal BP compared with the group who remained
re-hypertensive over the course of the study.
This trend to regression in the normotensive group has
ot been reported in any other IVUS-based trial except a
tudy using a short-term infusion of a high-density lipopro-
ein mimetic (apolipoprotein A-1 Milano phospholipids
omplex) (7) and a study lowering LDL to a mean of 61
g/dl with 40 mg rosuvastatin over a 24-month period (8).
his degree of effect on atheroma volume was not seen in
he REVERSAL (Reversal of Atherosclerosis With Ag-
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Editorial Comment August 15, 2006:839–40ressive Lipid-Lowering) trial, which produced an aggres-
ive level of LDL reduction to 79 mg/dl with 80 mg
torvastatin, although this trial was 18 months in duration
9). The significant changes in atherosclerosis were not
ffected by adjusting for the treatment arm, further suggest-
ng that the effect is due to BP and not the method of
etting there.
The authors should be commended for conducting such a
etailed, well-reported, and thought-provoking study. This
nalysis provides important mechanistic insights regarding
he relationship between systolic BP and progression of
oronary atherosclerosis. The study suggests that there is a
ontinuous relationship between systolic BP and the pro-
ression rate of coronary atherosclerosis, with benefits
xtending to levels of BP below 115/75 mm Hg. These
esults also suggest that to favorably effect the progression of
therosclerosis, decreasing the BP from a pre-hypertensive
evel to a normotensive level may be as important as
dministering intensive lipid-lowering treatment.
There are several issues that must be considered before
eneralizing these findings. Because this was a post hoc
nalysis, the patient groups studied differed in a number of
ther important characteristics besides BP. The hyperten-
ive group of patients were older, were more likely female,
nd had more assignment to the placebo arm. A prospective
ntention-to-treat trial with different BP targets would be a
referred design to evaluate the relationship between ath-
rosclerosis progression and target BP, maintaining other
reatment parameters equal. The number of subjects studied
s relatively limited, and this is a select cohort of patients
illing to consent to multiple IVUS evaluations. Patients
ith diastolic BP 100 mm Hg were excluded. There has
lso been some debate about the methodology used in IVUS
tudies of atheroma volume. There can be differences in the
ullback length between 2 anatomic points from the base-
ine IVUS study to the exam at 2 years, for example, the
istance between the left anterior descending (LAD)/
iagonal bifurcation and the left main/LAD bifurcation
ay vary up to 15%. Also, the length of artery that is
nterrogated may differ between patients. To address these
ssues, the core laboratory measured the total atheroma
olume per segment and then divided by the length to get
n average area of atheroma per patient. This value is then
ultiplied by the average length of artery imaged for all the
atients. This number is not necessarily the same as the
ctual atheroma volume for the patient’s segment of artery
hat was imaged. It would also be helpful if these IVUS
esults were reproduced by an independent core laboratory
eanalyzing the original data tapes.
This IVUS-based study is important, because it provides
orrelation between clinical findings and an anatomic justi-
cation for the results. If regression of coronary artery
isease is the desired outcome, then treatment to systolic BPevels well below current guideline recommendations is
etter. If true, there are millions of patients with coronary
rtery disease that would benefit from further reductions in
heir systolic BP. However, it is critical to note that the
egree to which regression documented by IVUS will
ranslate into a reduction in clinical events in patients with
oronary artery disease is unknown. Defining the optimal
lood pressure level in patients with established coronary
rtery disease will require randomized clinical trials suffi-
iently powered to detect differences in cardiovascular event
ates. Assessment of the benefits (and risks) of various blood
ressure levels within the so-called normal range and
ifferent BP-lowering strategies should be further evaluated
n such prospective trials. The important implication of this
tudy is that there is a critical need to reassess the guidelines
or managing BP in patients with coronary artery disease.
erhaps what has traditionally been considered “normal” BP
s not necessarily optimal nor healthy in patients with
oronary artery disease.
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